Skip to main content
. Author manuscript; available in PMC: 2023 Oct 10.
Published in final edited form as: Cancer Cell. 2022 Sep 29;40(10):1161–1172.e5. doi: 10.1016/j.ccell.2022.08.022

Figure 6: See also Tables S7-S8. Impact of MGA genomic alterations on overall survival (OS) in ICI-treated patients with NSCLC.

Figure 6:

A. OS in the DFCI NSCLC cohort of European ancestry. B. OS in the DFCI NSCLC cohort of African ancestry. C. OS in the DFCI NSCLC cohort of Asian ancestry. D. OS in the MSKCC NSCLC cohort of European ancestry. E. OS in the MSKCC NSCLC cohort of African ancestry. F. OS in the MSKCC NSCLC cohort of Asian ancestry. WT: Wild type. P-values were adjusted for prior lines of therapy, ICI type, TMB-c, treatment prior to sequencing and histologic subtype. See also Tables S7-S8.